Cargando…
Risks of using SSRI / SNRI antidepressants during pregnancy and lactation
At present, affective disorders are among the most commonly diagnosed mental diseases. In pregnancy, they can occur as pre-delivery depression, recurrent depressive disorder or postnatal depression. The estimated prevalence of depressive disorders in pregnancy is approximately 9–16%, with some stati...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Slovak Toxicology Society SETOX
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096863/ https://www.ncbi.nlm.nih.gov/pubmed/30123033 http://dx.doi.org/10.1515/intox-2017-0004 |
_version_ | 1783348183475159040 |
---|---|
author | Dubovicky, Michal Belovicova, Kristína Csatlosova, Kristína Bogi, Eszter |
author_facet | Dubovicky, Michal Belovicova, Kristína Csatlosova, Kristína Bogi, Eszter |
author_sort | Dubovicky, Michal |
collection | PubMed |
description | At present, affective disorders are among the most commonly diagnosed mental diseases. In pregnancy, they can occur as pre-delivery depression, recurrent depressive disorder or postnatal depression. The estimated prevalence of depressive disorders in pregnancy is approximately 9–16%, with some statistics reporting up to 20%. Approximately 2–3% of pregnant women take antidepressants during pregnancy, and the number of mothers treated increases by birth to 5–7%. Treatment of depression during pregnancy and breastfeeding is a controversial issue, as antidepressants can negatively affect the developing fetus. According to epidemiological studies, the effects of treated depression in pregnancy are related to premature birth, decreased body weight of the child, intrauterine growth retardation, neonatal adaptive syndrome, and persistent pulmonary hypertension. However, untreated depression can adversely affect maternal health and increase the risk of preeclampsia and eclampsia, as well as of subsequent postnatal depression, which can lead to disruption of the mother-child relationship. Based on the above mentioned facts, the basic question arises as to whether or not to treat depression during pregnancy and lactation. |
format | Online Article Text |
id | pubmed-6096863 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Slovak Toxicology Society SETOX |
record_format | MEDLINE/PubMed |
spelling | pubmed-60968632018-08-17 Risks of using SSRI / SNRI antidepressants during pregnancy and lactation Dubovicky, Michal Belovicova, Kristína Csatlosova, Kristína Bogi, Eszter Interdiscip Toxicol Minireview At present, affective disorders are among the most commonly diagnosed mental diseases. In pregnancy, they can occur as pre-delivery depression, recurrent depressive disorder or postnatal depression. The estimated prevalence of depressive disorders in pregnancy is approximately 9–16%, with some statistics reporting up to 20%. Approximately 2–3% of pregnant women take antidepressants during pregnancy, and the number of mothers treated increases by birth to 5–7%. Treatment of depression during pregnancy and breastfeeding is a controversial issue, as antidepressants can negatively affect the developing fetus. According to epidemiological studies, the effects of treated depression in pregnancy are related to premature birth, decreased body weight of the child, intrauterine growth retardation, neonatal adaptive syndrome, and persistent pulmonary hypertension. However, untreated depression can adversely affect maternal health and increase the risk of preeclampsia and eclampsia, as well as of subsequent postnatal depression, which can lead to disruption of the mother-child relationship. Based on the above mentioned facts, the basic question arises as to whether or not to treat depression during pregnancy and lactation. Slovak Toxicology Society SETOX 2017-09 2018-02-14 /pmc/articles/PMC6096863/ /pubmed/30123033 http://dx.doi.org/10.1515/intox-2017-0004 Text en Copyright © 2017 SETOX & Institute of Experimental Pharmacology and Toxicology, SASc. https://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License. (CC BY-NC-ND 4.0) |
spellingShingle | Minireview Dubovicky, Michal Belovicova, Kristína Csatlosova, Kristína Bogi, Eszter Risks of using SSRI / SNRI antidepressants during pregnancy and lactation |
title | Risks of using SSRI / SNRI antidepressants during pregnancy and lactation |
title_full | Risks of using SSRI / SNRI antidepressants during pregnancy and lactation |
title_fullStr | Risks of using SSRI / SNRI antidepressants during pregnancy and lactation |
title_full_unstemmed | Risks of using SSRI / SNRI antidepressants during pregnancy and lactation |
title_short | Risks of using SSRI / SNRI antidepressants during pregnancy and lactation |
title_sort | risks of using ssri / snri antidepressants during pregnancy and lactation |
topic | Minireview |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096863/ https://www.ncbi.nlm.nih.gov/pubmed/30123033 http://dx.doi.org/10.1515/intox-2017-0004 |
work_keys_str_mv | AT dubovickymichal risksofusingssrisnriantidepressantsduringpregnancyandlactation AT belovicovakristina risksofusingssrisnriantidepressantsduringpregnancyandlactation AT csatlosovakristina risksofusingssrisnriantidepressantsduringpregnancyandlactation AT bogieszter risksofusingssrisnriantidepressantsduringpregnancyandlactation |